Pharmaceutical

Servier and Black Diamond sign deal for solid tumours therapy

Servier and Black Diamond Therapeutics have signed a licencing agreement for targeted therapy, BDTX-4933, aimed at addressing solid tumours.

Mar 21, 2025 - 06:00
Servier and Black Diamond sign deal for solid tumours therapy
Servier and Black Diamond Therapeutics have signed a licencing agreement for targeted therapy, BDTX-4933, aimed at addressing solid tumours.
Read the original article

Tags:

Previous Article

Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody

Next Article

International Reference Pricing (IRP) 2024: A year in review

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: We’re reading about Lilly plant problems, FDA reorganization plans, and more

STAT+: Pharmalittle: We’re reading about Lilly plant pr...

Jan 22, 2024

AI is a pillar of tomorrow’s healthcare system, but limitations remain

AI is a pillar of tomorrow’s healthcare system, but lim...

Sep 29, 2023

Azenta in robotics: theme innovation strategy

Mar 5, 2024